AI Article Synopsis

  • A study investigated the effectiveness of 8-week vs. 12-week glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis C, focusing on both non-cirrhotic and cirrhotic patients in Japan.
  • The study enrolled 1,275 patients and primarily measured the sustained virological response (SVR) rates for different treatment durations and liver conditions.
  • Results showed high SVR rates (98.9% to 100%) across all groups, indicating that both 8-week and 12-week treatment regimens are effective regardless of liver fibrosis status.

Article Abstract

Background And Aim: In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non-cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated.

Methods: This prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non-cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated.

Results: The SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups ( = 0.4).

Conclusion: GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11046085PMC
http://dx.doi.org/10.1002/jgh3.13068DOI Listing

Publication Analysis

Top Keywords

chronic hepatitis
32
treatment periods
16
patients chronic
16
gle/pib therapy
16
treatment
12
8 weeks treatment
12
treatment cirrhosis
12
liver fibrosis
12
12 weeks treatment
12
glecaprevir pibrentasvir
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!